Asad Bashey, M.D., Ph. D.

<<Back To Our Physicians

Asad Bashey, M.D., Ph.D., is board certified in the subspecialties of medical oncology and hematology. He is the clinical research Medical Director for The Blood and Marrow Transplant Program at Northside Hospital. Dr. Bashey is also a Northside Hospital Leukemia and Immunotherapy Program physician. Dr. Bashey has been Atlanta's Top Doctor in his specialty from 2013 to 2024.

Training

  • University of Dundee in Scotland, where he graduated with Commendation

  • Residency training, University of Edinburgh, Scotland

  • Fellowship training in bone marrow transplantation and leukemia therapy at the Hammersmith Hospital (Royal Postgraduate Medical School, now Imperial College School of Medicine) in London, UK.

  • Awarded Ph.D. from the University of London for his research related to leukemia.

  • Fellowships: Hematology- Oncology and Blood and Marrow Transplant, University California, San Diego’s (UCSD) Moores Cancer Center in La Jolla, California

Society Memberships

  • American Society of Clinical Oncology

  • American Society of Hematology

  • American Society of Blood and Marrow Transplantation

Past Academic Faculty Appointments

  • UCSD Moores Cancer Center -Associate Professor: Clinical Director of the Bone Marrow Transplant Program and the Clinical Services Chief for the BMT Division.

Publications

  • Authored and co-authored more than 300 research articles and abstracts in peer-reviewed journals; New England Journal of Medicine, Blood, Journal of Clinical Oncology, Bone Marrow Transplantation, and Biology of Blood and Marrow Transplantation

  • Primary author of several books, including “Non-Myeloblative Allogeneic Transplantation” (2002) and “100 Questions and Answers on Myeloma” (2nd edition 2009), and Haplo Transplant Versus Cord Blood Transplant, Hematopoietic Transplantation: Bone Marrow, Blood and Cell Therapies.  Cambridge University Press, Cambridge, United Kingdom 2014: In press.

Dr. Bashey’s clinical and research interests include novel approaches to allogeneic bone marrow transplantation, strategies for augmentation of the graft-versus-tumor effect after allogeneic transplantation, and stem cell mobilization. He has received major clinical research funding from the National Institutes of Health.